XML 23 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common stock
Additional paid-in capital
Cumulative Effect Adjustment
Additional paid-in capital
AOCI Attributable to Parent
Accumulated deficit
Cumulative Effect Adjustment
Accumulated deficit
Cumulative Effect Adjustment
Total
Balance (in shares) at Dec. 31, 2018 50,606,147              
Balance at the beginning of the period at Dec. 31, 2018 $ 51   $ 1,288,137 $ 1,462   $ (938,923)   $ 350,727
Increase (Decrease) in Stockholders' Equity                
Equity component of convertible notes, net     119,482         119,482
Issuance of common stock related to equity offerings (in shares) 10,102,899              
Issuance of common stock related to equity offering $ 10   323,746         323,756
Exercise of options (in shares) 949,887              
Exercise of options $ 1   18,275         18,276
Restricted stock vesting and issuance (in shares) 169,792              
Restricted stock vesting and issuance, net               0
Issuance of common stock in connection with an employee stock purchase plan (in shares) 107,145              
Issuance of common stock in connection with an employee stock purchase plan     3,577         3,577
Share-based compensation expense     42,134         42,134
Net loss           (251,576)   (251,576)
Comprehensive income (loss)       (12,046)       (12,046)
Balance (in shares) at Dec. 31, 2019 61,935,870              
Balance at the end of the period at Dec. 31, 2019 $ 62   1,795,351 (10,584)   (1,190,499)   594,330
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock related to equity offerings (in shares) 542,470              
Issuance of common stock related to equity offering $ 1   28,091         28,092
Issuance of common stock related to acquisition (in shares) 845,364              
Issuance of common stock related to acquisition $ 1   42,868         42,869
Issuance of common stock related to rights exchange (in shares) 2,821,176              
Issuance of common stock related to rights exchange $ 3   150,525         150,528
Exercise of options (in shares) 3,268,452              
Exercise of options $ 3   70,176         70,179
Restricted stock vesting and issuance (in shares) 180,028              
Restricted stock vesting and issuance, net               0
Issuance of common stock in connection with an employee stock purchase plan (in shares) 124,736              
Issuance of common stock in connection with an employee stock purchase plan     5,303         5,303
Share-based compensation expense     70,325         70,325
Receivable from investor     9,107         9,107
Other           (218)   (218)
Net loss           (438,160)   (438,160)
Comprehensive income (loss)       (50,373)       (50,373)
Balance (in shares) at Dec. 31, 2020 69,718,096              
Balance at the end of the period at Dec. 31, 2020 $ 70 $ (175,236) 2,171,746 (60,957) $ 54,796 (1,628,877) $ (120,440) 481,982
Increase (Decrease) in Stockholders' Equity                
Exercise of options (in shares) 635,871              
Exercise of options $ 1   17,308         17,309
Restricted stock vesting and issuance (in shares) 307,658              
Restricted stock vesting and issuance, net               0
Issuance of common stock in connection with an employee stock purchase plan (in shares) 166,601              
Issuance of common stock in connection with an employee stock purchase plan     5,792         5,792
Share-based compensation expense     103,513         103,513
Receivable from investor     483         483
Other           25   25
Net loss           (523,901)   (523,901)
Comprehensive income (loss)       36,675       36,675
Balance (in shares) at Dec. 31, 2021 70,828,226              
Balance at the end of the period at Dec. 31, 2021 $ 71   $ 2,123,606 $ (24,282)   $ (2,097,957)   $ 1,438